Online webinar : Microalgae-Derived Antibodies: New Sustainable Tools for Research and Diagnostics

Date: Thursday, 15 October 2026 | Time: 11:00 CET

Join Alga Biologics for a webinar on microalgae as innovative cell biofactories for recombinant antibodies. Discover a new generation of Trastuzumab and Rituximab produced in microalgae — sustainable, high-performance alternatives for research and diagnostic applications.

Overview

Microalgae are emerging as innovative cell biofactories for recombinant antibodies, offering an attractive alternative to conventional mammalian cell-based production. In this webinar, we will introduce the potential of microalgae-derived antibodies for biomedical research and diagnostic applications.

Using Trastuzumab produced in the diatom Phaeodactylum tricornutum as a case study, we will showcase data demonstrating specific HER2 recognition and binding performance comparable to CHO-derived Trastuzumab. We will explore its performance across commonly used applications, including Western blot, ELISA, FACS and immunohistochemistry. We will also introduce Rituximab as another example of a monoclonal antibody produced using this innovative platform.

Join us to discover how microalgae-derived antibodies could provide a new generation of reliable and sustainable tools for your research and diagnostic workflows.

Register now to secure your place

Free registration via Zoom

Sustainable Production Platform

Microalgae offer a cost-effective, animal-component-free and environmentally friendly alternative to traditional mammalian cell culture for recombinant antibody production.

Comparable Performance to CHO

Trastuzumab produced in Phaeodactylum tricornutum shows specific HER2 recognition and binding performance on par with CHO-derived counterparts.

Validated Across Key Applications

Demonstrated functionality in Western blot, ELISA, FACS and immunohistochemistry — ready for research and diagnostic use cases.

Expanding Antibody Portfolio

Beyond Trastuzumab, explore Rituximab and a growing range of microalgae-derived monoclonal antibodies designed for research and IVD applications.

Meet the Speaker

Muriel Bardor

CEO/CSO, Alga Biologics
Professor EX2, University of Rouen Normandie, France

Muriel Bardor is an internationally recognized expert in recombinant protein and therapeutic antibody production, with pioneering expertise in microalgae as sustainable cell biofactories. As Professor at the University of Rouen Normandy and honorary member of the Institut Universitaire de France (IUF), she has led numerous European and national research and innovation projects in bioproduction and biotherapies.

With research and leadership experience in France, the United States and Singapore, Muriel combines scientific expertise with strong entrepreneurial and business skills. She is now fully dedicated to Alga Biologics, where she leads the development of innovative microalgae-based bioproduction technologies and antibody products.

Key Takeaways

New Sustainable Antibody Source

Understand how microalgae can serve as efficient, scalable biofactories for high-quality recombinant monoclonal antibodies.

Performance Data You Can Trust

Review comparative data on Trastuzumab (and introduction to Rituximab) showing binding specificity and application performance versus conventional CHO-produced antibodies.

Ready for Research & Diagnostics

See how these microalgae-derived antibodies perform in Western blot, ELISA, flow cytometry (FACS) and immunohistochemistry workflows.

Target Audience

This webinar is intended for professionals working with antibodies in research, diagnostics and related fields, including:

Researchers in biochemistry, immunology, cell biology and oncology
Flow cytometry users and immunophenotyping laboratories
Core facilities and shared resource laboratories
Immunohistochemistry specialists
Diagnostic and IVD professionals
Scientists exploring sustainable alternatives for antibody reagents

Why Microalgae-Derived Antibodies?

Microalgae represent a promising next-generation platform for producing research- and diagnostic-grade antibodies. Key advantages include:

Sustainable, animal-component-free production using photosynthetic microalgae
High-quality recombinant antibodies with performance comparable to CHO-derived products
Demonstrated functionality of Trastuzumab across Western blot, ELISA, FACS and IHC
Introduction of Rituximab as an additional monoclonal antibody from the same platform
Potential to reduce costs and environmental impact associated with conventional mammalian cell culture
Ideal for research tools and diagnostic applications requiring reliable, well-characterized reagents

Discover how this innovative approach can support more sustainable and efficient workflows in your laboratory.

Don’t miss this opportunity

Thursday, 15 October 2026 | 11:00 CET